Advanced esophageal cancer treatment continues to evolve as research provides new options for people living with locally advanced, recurrent, unresectable, or metastatic disease. ECEF has created this resource library to help patients, caregivers, and families explore current articles and research on advanced and stage 4 esophageal cancer, including chemotherapy, immunotherapy, targeted therapies, clinical trials, supportive care, survival, and emerging treatment approaches. Articles are selected from external medical, research, and news sources and link to the original publication for further reading.
As part of our coverage of ASCO’s 2017 Gastrointestinal Cancers Symposium held January 19th to the 21st in San Francisco, today we are speaking with Dr. Geoffrey Ku, MD, a medical oncologist with Memorial Sloan…
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices, according to a new study. http://www.cancernetwork.com/gastrointestinal-cancer/novel-calculator-guides-treatment-choice-esophageal-cancer
Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, compared with chemotherapy…
Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk of disease progression or death,…
The immune checkpoint inhibitor Opdivo (nivolumab) may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest.…
Opdivo demonstrated a significant improvement over chemotherapy, with a 23% reduction in risk of death and a 2.5-month improvement in the median time patients survived, compared to those on chemotherapy. Opdivo’s safety profile was consistent…
A tweaked version of a cellular immunotherapy that recognizes mutations in a patient’s tumor has led to the complete regression of metastatic breast cancer in a woman whose disease had failed to respond to multiple…
